Cipla soars as its arm inks distribution pact with Serum Institute of India

Cipla is currently trading at Rs. 632.00, up by 13.40 points or 2.17% from its previous closing of Rs. 618.60 on the BSE. The scrip opened at Rs. 625.00 and has touched a high and low of Rs. 645.00 and Rs. 625.00 respectively. So far 211954 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 671.95 on 31-Oct-2014 and a 52 week low of Rs. 366.70 on 24-Feb-2014. Last one week high and low of the scrip stood at Rs. 645.00 and Rs. 593.25 respectively. The current market cap of the company is Rs. 50684.41 crore. The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 34.67% and 27.38% respectively. Cipla’s wholly owned subsidiary, Cipla Europe NV has signed a distribution agreement with Serum Institute of India (SII), a global leader in the production of vaccines. Under the agreement, SII will develop and manufacture paediatric vaccines, while Cipla will seek European Medicines Agency approval and market the products in Europe. This collaboration with SII enables Cipla to enter into the vaccines segment, continuing our commitment to inclusive healthcare for the world. The vaccines will be manufactured in Serum’s world class production facilities approved by World Health Organisation (WHO). Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.